Manipulating Cardiomyocyte Plasticity for Heart Regeneration

Toshiyuki Ko and Seitaro Nomura*

Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

Pathological heart injuries such as myocardial infarction induce adverse ventricular remodeling and progression to heart failure owing to widespread cardiomyocyte death. The adult mammalian heart is terminally differentiated unlike those of lower vertebrates. Therefore, the proliferative capacity of adult cardiomyocytes is limited and insufficient to restore an injured heart. Although current therapeutic approaches can delay progressive remodeling and heart failure, difficulties with the direct replenishment of lost cardiomyocytes results in a poor long-term prognosis for patients with heart failure. However, it has been revealed that cardiac function can be improved by regulating the cell cycle or changing the cell state of cardiomyocytes by delivering specific genes or small molecules. Therefore, manipulation of cardiomyocyte plasticity can be an effective treatment for heart disease. This review summarizes the recent studies that control heart regeneration by manipulating cardiomyocyte plasticity with various approaches including differentiating pluripotent stem cells into cardiomyocytes, reprogramming cardiac fibroblasts into cardiomyocytes, and reactivating the proliferation of cardiomyocytes.

Keywords: heart failure, myocardial infarction, reprogramming, regeneration, cardiomyocyte proliferation

INTRODUCTION

Despite decades of development of therapeutic approaches, cardiovascular disease remains the leading cause of morbidity and mortality worldwide, accounting for an estimated 18.6 million deaths annually in the United States (Aparicio et al., 2021). Along with the brain, the adult mammalian heart is arguably one of the least regenerative organs, and cardiomyocytes (CMs) are considered to be terminally differentiated. CMs account for approximately 75% of the left ventricular volume in healthy adults (Vliegen et al., 1991). They facilitate the pumping of blood into the circulatory system by coordinating contraction and diastole. Therefore, any massive injury to the heart will induce progression to heart failure, resulting in the death of CMs, which become replaced with fibrotic scar tissue (Fu et al., 2018; Le Bras, 2018; Yokota et al., 2020). One of the most common pathological heart injuries is myocardial infarction, which is accompanied by the massive irreversible loss of CMs. Since mature CMs have little regenerative capacity, the remaining CMs cannot fully proliferate and restore lost cells. Compensatory scarring to replace dead tissue with cardiac fibroblasts leads to heart remodeling, which ultimately reduces cardiac systolic function and induces heart failure and sudden cardiac death (Jenča et al., 2021). Therapies for heart failure have decreased mortality, but evidence has yet to support the notion that CMs can regenerate or that lost CMs can be replaced in patients who undergo such therapies. Although heart transplantation is feasible and effective for advanced heart failure (Chambers et al., 2021), donor hearts are scarce and multiple post-transplant complications have limited their application. Therefore, heart regeneration has attracted interest as a novel approach to treating heart failure. The approaches to heart regeneration currently comprise differentiating pluripotent stem cells (PSCs) into CMs, reprogramming cardiac fibroblasts...

*Correspondence: Seitaro Nomura senomura-cib@umin.ac.jp

Specialty section: This article was submitted to Molecular and Cellular Pathology, a section of the journal Frontiers in Cell and Developmental Biology

Received: 26 April 2022
Accepted: 14 June 2022
Published: 11 July 2022

Citation: Ko T and Nomura S (2022) Manipulating Cardiomyocyte Plasticity for Heart Regeneration. Front. Cell Dev. Biol. 10:929256. doi: 10.3389/fcell.2022.929256
Heart Regeneration Using Pluripotent Stem Cells

Human PSCs consist mainly of embryonic (ESCs) and induced pluripotent (iPSCs) stem cells. Cellular reprogramming and iPSC generation were discovered in 2007 (Takahashi et al., 2007). Several approaches have since been used to differentiate iPSCs into CMs (iPSC-CMs). Transplanted iPSC-CMs improved cardiac function and survival after myocardial infarction in animal models (Shiba et al., 2016; Park et al., 2019). In addition, recent studies have already established tumorigenicity assay system to detect malignantly transformed cells within iPSC-CMs (Sougawa et al., 2018; Ito et al., 2019). Transplanted iPSC-CMs can trigger an immune response mediated by natural killer cells, resulting in low engraftment (Nakamura et al., 2019), and immature iPSC-CMs might lead to ventricular tachycardia (Shiba et al., 2016). Differentiation methods described so far have been limited by the inability to generate mature CMs, which are diferent from fetal CMs in terms of function, morphology, and electrophysiology (Gomez-Garcia et al., 2021).

Several studies have attempted to improve the low engraftment rate of transplanted cells and enhance the maturity of iPSC-CMs (Protez et al., 2019). Tissue engineering has improved the engraftment rate and therapeutic effects of transplanted cells using scaffolds such as hydrogels (Chow et al., 2017), cell sheets (Kawamura et al., 2017), cardiac patches (Gao et al., 2018; Zhu D. et al., 2021; Querdel et al., 2021), and three-dimensional bio-printed tissues (Gao et al., 2017; Kawai et al., 2022). Activating Wnt/β-catenin signaling promotes human PSC differentiation and the production of high-purity (up to 98%) iPSC-CMs (Lian et al., 2012). A Gsk3β inhibitor combined with Wnt-C59 contributes to the production of high-purity iPSC-CMs (Burridge et al., 2014). Glucose and glutamine depletion eliminates residual undifferentiated human PSCs after CM differentiation (Tohyama et al., 2016). Other recent endeavors to improve the maturity of iPSC-CM include long-term culture (Fbert et al., 2019; Funakoshi et al., 2021), metabolic substrates (Hu et al., 2018; Gentillon et al., 2019; Miklas et al., 2019; Garbern et al., 2020) and miRNAs (Kuppusamy et al., 2015).

In terms of clinical application of iPSC-CMs, a clinical trial of allogeneic iPSC-CM sheets for patients with ischemic cardiomyopathy has started (ClinicalTrials.gov, #jRCT2053190081). The safety and efficiency of transplantation of human iPSC-derived cardiac spheroids (CSs) has been shown using swine heart failure model (Kawaguchi et al., 2021). These seem to be a feasible way to improve cardiac function in patients with heart failure. Although PSC-based heart regeneration has potential for treating severe heart failure, considering their immaturity of iPSC-CM and poor survival of transplanted cells, further investigation of its safety and efficacy is still required. From therapeutic perspective, since the differentiation and preparation of iPSC-CMs is a long process, its transplantation will be limited only to the patients with chronic heart failure. Besides, the current intramyocardial transplantation of iPSC-CMs needs open-chest surgery, which will be high risk for the patients with severe heart failure. Development of a less invasive transplant methods such as catheter delivery may be helpful.

Reprogramming non-CMs for Heart Regeneration

Although CMs account for approximately 75% of the normal myocardial tissue volume, they constitute only 40% of the total
Cardiac fibroblasts are among the most important non-CM components of the heart. Upon myocardial infarction, they are activated and recruited to the injured site to form scar tissue (Tallquist and Molkentin, 2017; Fu et al., 2018). Given that the number of CFs can be increased by the proliferation of resident CFs in injured heart tissue, reprogramming this abundant cell population into functional CMs would be an ideal strategy for heart repair in response to ischemic injury. The process of converting somatic cells from one lineage to another without transitioning through a stem cell state is called direct reprogramming (or transdifferentiation; Figure 2) (Wang H. et al., 2021). Compared with the generation of iPSC-CMs, direct reprogramming of CFs into CMs enables more rapid and efficient conversion of cells in situ without the need for cell expansion ex vivo and transplantation. Three years after the epoch-making discovery of iPSCs (Takahashi et al., 2007), the combined transcription factors Gata4, Mef2c, and Tbx5 (GMT) were found to directly convert CFs into CM-like cells which show the organized sarcomeric structures, global CM-like gene expression profiles, action potentials, and spontaneous contractions (Ieda et al., 2010). Reprogramming CFs into CMs requires inhibiting fibroblast signatures, extensive chromatin remodeling to overcome existing epigenetic barriers, and the simultaneous acquisition of a CM-like chromatin profile. Several groups then found that adding or modifying core reprogramming factors in addition to GMT such as other transcription factors, kinases, and microRNAs (miRs), might further promote direct reprogramming and CM maturation. Other transcription factors and kinases which enhance the efficiency of reprogramming includes Heart- and Neural Crest Derivatives-Expressed Protein 2 (Hand2) (Song et al., 2012; Nam et al., 2014), NK2 homeobox 5 (Npk2-5) (Addis et al., 2013), Mesoderm Posterior bHLH Transcription Factor 1 (Mesp1) and Myocardin (Wada et al., 2013), Estrogen Related Receptor Gamma (ESRRG), MESP1, MYOCID, and Zinc Finger Protein Multitype (ZFPM) (Fu et al., 2013), and AKT and HAND2 (Zhou et al., 2015). The transcription factor Guanine-Adenine-Thymine-Adenine (GATA) 4 is thought to have the potential for human and mouse cardiac reprogramming, whereas Myocyte-Specific Enhancer Factor 2C (MEF2C) and T-Box Transcription Factor 5 (TBX5) are important for activating cardiac gene expression to initiate CM maturation (Liu et al., 2017; Hashimoto et al., 2019; Stone et al., 2019). Addition of miR-133 to either GMT or GMT + Myocd + Mesp1 promoted CM reprogramming efficiency and maturation (Muraoka et al., 2014). Addition of miR-1 and miR-133 to GMT + HAND2 (GHMT) (Nam et al., 2013) or GMT + MYOCID + NKX2.5 (Christoforou et al., 2017) accelerated CM reprogramming and upregulates cardiac gene expression. Mechanistically, miR-133 directly targets Snai1, a master regulator of epithelial-to-mesenchymal transition, and represses its protein production (Muraoka et al., 2014). The combination of muscle-specific miR-1, miR-133, miR-208, and miR-499 (miR combo) could be an alternative to overexpressing transcription factors for directly reprogramming CFs into CMs (Jayawardena et al., 2012, 2015). The miR combo induces the expression of endogenous reprogramming factors GHMT (Dal-Pra et al., 2017).

As direct reprogramming requires chromatin remodeling to transform CFs into CMs, transcription factors such as GMT must be able to engage genes that are developmentally silenced for expression in fibroblasts. Therefore, epigenetic factors play important roles in promoting or inhibiting cardiac reprogramming. Analyses of epigenetic status have revealed that the inactive heterochromatin-associated histone mark H3K27me3 increases at fibroblast promoters and decreases at cardiac promoters, whereas activated chromatin marks (H3K4me3 and H3K27ac) were enriched at cardiac promoters during direct reprogramming (Fu et al., 2013; Liu et al., 2016; Dal-Pra et al., 2017; Riching et al., 2021). Promoters of the cardiac genes, such as NPPA and MYH6, are similarly demethylated immediately after GMT induction during reprogramming to CMs (Roost et al., 2017). Efforts to improve direct reprogramming have included manipulating epigenetic factors by knockdown of Bmi1 (Zhou et al., 2016) and Ezh2 (Hirai and

![Figure 2](https://example.com/figure2.png)

**FIGURE 2** | Molecular mechanisms involved in direct reprogramming of cardiac fibroblasts into cardiomyocytes. Major methods include TFs-based approach and non-TFs-based approach. Besides, various epigenetic factors and environmental factors also affect the efficiency of direct reprogramming. TFs, transcription factors; miR, microRNA.
Kikyo, 2014; Tang et al., 2021) and overexpression of PHF7 (Garry et al., 2021).

Small molecules that enhance the efficiency of direct reprogramming have been added to GMT or GHMT (Zhao et al., 2015; Mohamed et al., 2017). In contrast, fibroblasts have been directly reprogrammed to differentiate into CMs in mice using a cocktail containing CHIR99021, RepSox, Forskolin, Valproic Acid, Parnate, and (E)-4-[2-(5,7,8-tetrahydro-5,8,8-tetramethyl-2-naphthyl)-propen-1-yl]benzoic acid (TTNB) (CRFVPT), and the small molecule combination CRFVPT + DZNep (CRFVPTZ) induced iPSCs from embryonic fibroblasts (Hou et al., 2013; Fu et al., 2015). The Bmi1 inhibitor PTC-209 promotes the efficiency of direct reprogramming using CRFVPT (Testa et al., 2020). A similar protocol showed that a combination of nine compounds that partially overlapped with CRFVPT is sufficient and necessary to induce the direct reprogramming of human fibroblasts (Cao et al., 2016). Upon transplantation into the infarcted hearts of immunodeficient mice, these human fibroblasts were efficiently converted into CMs that expressed CM markers and developed organized sarcomeric structures. However, such chemically converted CMs lack an organized sarcoplasmic reticulum and transverse tubule structures, which are typical of adult CMs, suggesting the electric and mechanical immaturity. Therefore, further investigations are required to establish the optimal chemical conditions for CM maturation.

The local environment might also influence the efficiency of direct reprogramming (Van Handel et al., 2022). High-throughput screening showed that dicrofnenc enhances cardiac reprogramming by inhibiting cyclooxygenase-2-mediated prostaglandin E2/prostaglandin E receptor 4 signaling; this silences inflammation in aged fibroblasts that express more cyclooxygenase-2 than embryonic fibroblasts (Muraoka et al., 2019). Similarly, unbiased screening of transcription factors uncovered Znf281 as an inducer of direct reprogramming in murine CFs and showed that Znf281 enhanced CM generation by suppressing inflammatory gene expression while modulating cardiac gene expression (Zhou et al., 2017). Collectively, inflammation appears to be an important hurdle for direct reprogramming in mouse. However, there is apparent discrepancy between mouse and human reprogramming because some studies showed that inflammation and immune responses are required for direct reprogramming of human fibroblasts into CMs (Stone et al., 2019; Zhou et al., 2019). In addition to inflammation, previous studies showed that the efficiency of direct reprogramming as well as CM maturation is likely to be more efficient in vivo rather than in vitro; indicating that the cardiac microenvironment could be a favorable factor for reprogramming (Qian et al., 2012; Song et al., 2012; Jayawardena et al., 2015). Cardiac injury and subsequent myofibroblast activation are essential for CM generation (Qian et al., 2012; Song et al., 2012). Successfully reprogrammed cells exit the cell cycle early, indicating that proliferation might be detrimental to cardiac reprogramming (Liu et al., 2016; Zhou et al., 2019). The stiffness of extracellular environment would also affect the efficiency of direct reprogramming. The polystyrene culture dishes which are used for in vitro culture have a hardness of 1 GPa (≈ 1 × 10⁶ kPa), which is much harder than the heart tissue (around 10 kPa) in vivo. Recent report showed that soft extracellular matrix matrix promotes cardiac reprogramming and improves the maturity of generated CMs through the inhibition of YAP/TAZ and suppression of fibroblast signatures (Kurotsu et al., 2020).

Cardiac repair and regeneration in vivo are the goals of direct programming using the retroviral or lentiviral delivery of reprogramming cocktails (GMT, GHMT, and miR combo). These cocktails improve cardiac function and reduce fibrosis in a murine myocardial infarction model (Inagawa et al., 2012; Qian et al., 2012; Song et al., 2012; Jayawardena et al., 2015). However, integrative viral vectors, retroviruses, and lentiviruses present major concerns regarding possible mutagenetic effects such as the random genomic integration of virally overexpressed reprogramming factors. Therefore, non-integrative Sendai virus (SeV) vectors have been developed (Ieda et al., 2010). Direct reprogramming using SeV vectors considerably improved cardiac function and reduced fibrosis compared with retroviral vectors (Miyamoto et al., 2018). Direct reprogramming generates CMs mainly through bona fide cardiac reprogramming and not through fusion events between CMs and CFs (Isomi et al., 2021). Recently, nanotechnology-based approaches for direct reprogramming have recently attracted interest (Liu et al., 2021). Several studies have used nanoparticles or fused polyarginine-lipofectamine complexes to generate iPSCs in vitro or involved them in direct reprogramming (Zhu et al., 2014; Lee et al., 2015). Cationic gold nanoparticles that can load GMT expression plasmids for direct CF reprogramming recovered cardiac function and reduced fibrosis in a murine model of myocardial infarction (Chang et al., 2019). A similar approach using a nanocarrier to deliver a miR combination resulted in efficient direct reprogramming and recovered cardiac function after myocardial infarction (Yang et al., 2021). Nanoparticles with the natural inflammation-homing ability and high affinity for CFs can specifically target cardiac fibroblasts in the injured heart (Wang H. et al., 2021). Nanoparticles intravenously injected into an infarcted heart delivered the miR combo into fibroblasts and improved cardiac function via efficient reprogramming.

Reprogramming CFs into CMs in vivo is a powerful and attractive alternative strategy for myocardial regeneration. Compared with transplantation of iPSC-CMs, in vivo direct reprogramming is simple and fast, and can be used as a treatment for patients with acute heart failure after myocardial infarction. To date, the considerable effort by numerous research groups has targeted the dissection of direct reprogramming to find effective protocols using transcription factors, miRs, and chemical compounds (Wang Q. et al., 2021). Regardless of substantial progress, further studies are warranted to assess the efficacy and safety of these approaches to heart regeneration before attempting clinical trials. The in vivo study using large animals whose heart rate is similar to human will be especially important because incidence of arrhythmias after treatment may be different depending on heart rate. Besides, many in vivo direct reprogramming studies showed that generation of CMs from CFs tend to be seen in the ischemic border zone (Qian et al., 2012;
Song et al., 2012; Jayawardena et al., 2015). Since CFs are rich in heterogeneity, probability of reprogramming might be different among each population of CFs. Therefore, comprehensive understanding of the cellular characteristics of CFs by single-cell analysis will be important. Furthermore, since all studies of direct reprogramming \textit{in vivo} involved mouse models of myocardial infarction, it is of significant interest whether reprogramming \textit{in vivo} could translate effectively to non-ischemic causes of heart failure.

**Proliferation of Extant CM for Heart Regeneration**

The ability to regenerate damaged myocardial tissue varies amongst vertebrates (Vivien et al., 2016; Velayutham et al., 2019). Some lower vertebrates such as zebrafish and amphibians can regenerate their hearts, but no adult mammalian species can robustly regenerate their hearts. The human heart can produce new adult CMs throughout the life, whereas the rate of CM division is very low (Lázár et al., 2017). However, fetal and early neonatal mammals have such abilities (Lam and Sadek, 2018). In addition, terminally differentiated myocytes can re-enter the cell cycle and divide through manipulation of the CM cell cycle, signaling pathways, miRs, and environmental factors. Inducing CM cell-cycle entry and heart repair is emerging as an effective strategy to compensate for lost functional CMs and improve impaired heart function (Figure 3).

**Intervention Using Cell Cycle Genes**

Cyclins and their related kinases (CDKs) regulate the cell-cycle transition phase from G1 to S, induce DNA synthesis, and maintain cell-cycle activity. More specifically, cyclins A/D/E are involved in DNA synthesis, whereas cyclin B mainly regulates cytokinesis. In contrast, complexes of cyclins/CDKs in adult mammalian CMs are constitutively inhibited by the CIP/KIP family (p21, p27, and p57) and the INK4 family (p16, p15, p18, and p19). Since the decline in the proliferative capacity of post-mitotic CMs might be due to the downregulation of cyclins/CDKs and upregulation of CIP/KIP family and INK4 family, whether the intervention with these cell-cycle regulators might induce CM cell-cycle entry has been widely investigated (Salama et al., 2021). For example, overexpression of cyclin A2 in murine and porcine infarcted hearts improved heart function, and activated the cell cycle in CMs (Woo et al., 2006; Cheng et al., 2007; Shapiro et al., 2014). Inhibition of the CIP/KIP family increased expression of cyclins and reactivated the cell cycle in CMs (Di Stefano et al., 2011). Inactivating Retinoblastoma 1 (RB1) and cyclin-dependent kinase inhibitor 2a (CDKN2A) or downregulating p21 can induce CMs to enter mitosis and synthesize DNA (Hatzistergos et al., 2019; Volland et al., 2020). The roles of other cyclins and CDKs (such as cyclin D1, D2, B1, CDK2, and CKD4) in the re-entry of CMs into the cell cycle have been investigated. However, reactivating CM cell cycle activity and promoting DNA synthesis alone results in multinucleation or polyploidy without complete CM cytokinesis. Combinations of various cell-cycle genes may be more efficient in activating the cell cycle in CMs. Overexpressing the cell-cycle genes CDK1, CDK4, cyclin B1, and cyclin D1 (4F) induced stable cell cycle division (determined by EdU and PHH3) in 15%-20% of the adult mouse CMs, rat CMs, and iPSC-CMs, which robustly completed cytokinesis \textit{in vivo} (Mohamed et al., 2018). A polycistronic non-integrating lentivirus encoding 4F, in which each of the four factors was driven by CM-specific Troponin T2 significantly improved systolic function and reduced the size of scars after ischemic reperfusion in rats and pigs (Abouleisa et al., 2022). These findings indicated that modulating cell-cycle components is a promising strategy for unlocking the proliferative potential of CMs in the injured adult heart.

**Intervention With Transcription Factors**

The cell cycle is controlled by a complex regulatory network, and several cell-cycle-associated transcription factors such as the E2F family, T-Box Transcription Factor 20 (Tbx20), and Myeloid ecotropic viral integration site 1 (Meis1) have been verified as
potential initiators or drivers that could promote mammalian CM cell-cycle re-entry.

The E2F family includes a series of transcription factors that can bind to the adenovirus E2 promoter and activate viral genes. These factors play fundamental roles in DNA replication and cell cycle progression by regulating the expression of several cell cycle-associated genes. Overexpression of E2F2 in mice significantly increased the number of Bromodeoxyuridine (BrDU), Phosphohistone H3 (PHH3), and Aurora kinase-positive CM nuclei, suggesting that E2F2 not only induces DNA synthesis, but also promotes CMs to complete the entire cell cycle (Ebelt et al., 2008). The regulatory pocket protein of E2F, Rb combines with E2F2 and inhibits its activation. Phosphorylation of Rb by CDK2 and CDK4 induces Rb dissociation from E2F2, thus triggering the expression of DNA synthesis-associated genes and leading to increased CM cycling (MacLellan et al., 2005; Sdek et al., 2011). Furthermore, E2F2 suppresses the expression of pro-apoptotic genes in CMs (Ebelt et al., 2005) and E2F4 is required during the G2/M phase through the induction of cyclins A and E (Van Amerongen et al., 2010).

T-box family transcription factor 20, is essential for early heart development and adult heart function in various organisms. Deletion of Tbx20 resulted in embryonic death during mid-gestation (Chakraborty et al., 2013). A Tbx20 mutation causes CM arrest at the G1/S phase transition and reduces proliferation in zebrafish. In contrast, overexpression of Tbx20 enhanced the proliferation of differentiated CMs, resulting in an enlarged heart with significantly more CMs (Lu et al., 2017). Consistently inducible CM-specific Tbx20 KO in adult mice resulted in the onset of severe cardiomyopathy accompanied by arrhythmias and death within 1–2 weeks of Tbx20 ablation (Shen et al., 2011). In contrast, overexpression of Tbx20 promoted mature CM proliferation in mice and resulted in increased numbers of small, mononucleated CMs by activating the BMP2/pSmad1/5/8 and PI3K/AKT/GSK3β-β-catenin signaling pathways (Chakraborty et al., 2013), while repressing expression of the cell-cycle inhibitors p21, Meis1, and B-cell translocation gene 2 (Btg2) (Xiang et al., 2016). T-Box Transcription Factor 20 participates in the regulation of angiogenesis through the signaling cascade of Tbx20-PROK2-PROKR1 (Meng et al., 2018). Like Tbx20, Tbx6 also promotes CM proliferation by upregulating multiple cell-cycle activators and suppressing Rb1 (Haginiwa et al., 2019).

The essential regulator of heart development Meis1 belongs to the three-amino acid loop extension (TALE) homeobox gene family (Paige et al., 2012; Wamstad et al., 2012) and it limits the postnatal proliferation capacity of CMs. Abundant Meis1 expression in P7 CMs correlates with postnatal cell-cycle arrest (Mahmoud et al., 2013). The CM proliferative capacity in postnatal mice with Meis1 KO was extended for up to 14 days without deleterious effects on cardiac function or induced hypertrophy, whereas overexpression of Meis1 inhibited neonatal cell proliferation and neonatal heart regeneration. Mechanistically, Meis1 regulates transcription of the CDK inhibitors p15, p16, and p21 (Mahmoud et al., 2013) and regulates cardiac metabolism. Knockdown of Meis1 in cultured CMs increased respiratory capacity and mitochondrial activity while decreasing glycolytic gene expression (Lindgren et al., 2019).

Other transcription factors that promote CM cell-cycle entry include Gata4 (Malek Mohammadi et al., 2017) and Hox13 (Nguyen et al., 2020). Some studies have focused on inducing CM dedifferentiation to promote cell proliferation. The induction of Klf1 directed epigenetic reprogramming of the cardiac transcription factor network in the injured adult zebrafish myocardium and permitted coordinated CM dedifferentiation and proliferation (Ogawa et al., 2021). The CM-specific expression of Oct4, Sox2, Klf4, and c-Myc (OSKM) induced adult CM dedifferentiation and confers regenerative capacity upon adult hearts (Chen et al., 2021). These attempts are similar to direct reprogramming in vivo. Although overexpression of transcription factors seems an attractive way to promote CM proliferation, the efficiency and safety requires further investigation. Novel methods allowing precise temporal overexpression of reprogramming factors are also important.

**Intervention Using Noncoding RNAs**

Only 1%–2% of genes in the mammalian genome encode proteins, and the rest are transcribed into noncoding (nc) RNAs that include micro (mi), long noncoding (lnc) and circular (circ) types. Noncoding RNAs play key roles in gene regulation during development, as well as in health and cardiovascular diseases (Poller et al., 2018). The overexpression of miR-199a, which accelerated CM entry into the cell cycle, also promoted cardiac repair, increased muscle mass, and resulted in improved cardiac systolic function in infarcted pig hearts (Eulalio et al., 2012; Gabisonia et al., 2019). The miR-302-367 cluster is expressed in the early developmental stage of mouse hearts and participates in modulating CM proliferation during the embryonic stage. Its overexpression promoted CM proliferation, probably by inhibiting the Hippo signaling pathway and reducing the size of scars after myocardial infarction (Barroso-del Jesus et al., 2008; Tian et al., 2015). MicroRNA-128 suppressed expression of the chromatin modifier SUZ12, which suppresses the CDK inhibitor p27, and activated cyclin E and CDK2. The proliferation period of neonatal mouse CMs was prolonged by miR-128 KO, and scar size and cardiac function after myocardial infarction was improved in adult miR-128 KO mice (Huang et al., 2018). MicroRNA-294 is expressed during prenatal development, but not in adult CMs. The ectopic transient expression of miR-294 recapitulated developmental signaling in CMs and promoted cell-cycle re-entry, which leads to improved cardiac function after myocardial infarction in mice (Borden et al., 2019). Long noncoding RNAs (>200 nt in length) play crucial roles in heart regeneration by promoting the proliferation of extant CMs (Han and Yang, 2021). Long noncoding RNAs associated with CM proliferation include cardiomyocyte regeneration-related IncRNA (CRRL) (Chen et al., 2018), cardiac regeneration-related IncRNA (CAREL) (Cai et al., 2018), CM proliferation regulator (CPR) (Ponnusamy et al., 2019), and endogenous cardiac regeneration-associated regulator (ECRAR) (Chen et al., 2019). Circular RNAs are IncRNAs that are characterized by a covalently closed loop structure, stable
expression, and resistance to nucleases due to not having 3’ poly(A) tails and 5’ cap structures (Mester-Tonczar et al., 2020). The expression of most known circRNAs is cell-and tissue-specific and they can interact with RNA-binding proteins to form complexes that promote the expression of downstream targets. For example, circFndc3b modulates cardiac repair after myocardial infarction by interacting with the RNA-Binding Protein Fused In Sarcoma (FUS) to promote Vascular Endothelial Growth Factor (VEGF) expression (Ganikapati et al., 2019) in endothelial cells. In addition, circRNA, as a miRNA sponge, regulates the expression of its downstream molecules, ultimately activating or inactivating relevant signaling pathways and generating corresponding biological functions (Hansen et al., 2013). Silencing circRNA Homeodomain-Interacting Protein Kinase 3 (HIPK3), which sponges nine miRNAs with 18 potential binding sites, significantly inhibited human cell growth (Zheng et al., 2016). Expression of the circHIPK3 is relatively abundant in the fetal and neonatal murine CM, and knockdown or overexpression of circHIPK3 respectively inhibited and increased CM proliferation in vitro and in vivo (Si et al., 2020).

**Intervention via Regulation of Signaling Pathways**

Hippo, Notch, HIF-1α-regulated cell stress, and NRG1/ErbB4 are among the numerous signaling pathways that are involved in CM proliferation (Zhu Y. et al., 2021).

The Hippo pathway plays a pivotal role in determining heart size by regulating CM proliferation, differentiation, and apoptosis (Xin et al., 2013; Tian et al., 2015; Ikeda et al., 2019). The activation of this pathway leads to phosphorylation of the transcriptional co-activators Yes-associated protein (YAP) and Tafazzin (Taz) and the prevention of cell proliferation and regeneration. Inhibited Hippo signaling during heart development promotes CM proliferation and leads to cardiomegaly (Heallen et al., 2011). Deletion of the Hippo pathway component Salv in murine hearts after myocardial infarction induced a reparative genetic program with increased scar border vascularization, reduced fibrosis, and reversed systolic function (Leach et al., 2017). Activation of YAP activity by either an AAV9 vector or a small molecule after myocardial infarction induced a reparative genetic program with increased scar border vascularity, reduced fibrosis, and reversed systolic function (Leach et al., 2017). Activation of YAP activity by either an AAV9 vector or a small molecule after myocardial infarction enhanced CM proliferation and improved heart function (Lin et al., 2013). The extracellular matrix protein Agrin, which is expressed mainly in endothelial cells, promotes the division of CMs partially through Yap-mediated signaling (Bassat et al., 2017). Agrin is also essential for epicardial epithelial-to-mesenchymal transition during heart development (Sun et al., 2021), suggesting the importance of extracellular matrix for the regulation of cellular plasticity and proliferation.

The Notch pathway controls cellular proliferation and trabeculation in developing hearts by activating bone morphogenetic protein BMP10, which increases CM entry into the cell cycle by downregulating cell-cycle inhibitors p21, p27, and p75 (Chen et al., 2004; Grego-Bessa et al., 2007). Other reports using zebrafish after ventricular resection revealed that Notch receptors are upregulated in endocardium and epicardium, but not in CMs. Endocardial Notch signaling increases the expression of secreted Wnt antagonists (for example, Wif1 and Notum1b) and thereby suppresses hyperactivation of Wnt signaling to support CM proliferation (Zhao et al., 2014, 2019).

Hypoxia-related cell stress signaling, which is mainly regulated by HIF-1α, plays an important role in CM cell-cycle arrest and proliferation. A metabolic switch in the perinatal heart from anaerobic to aerobic is associated with the exit of CMs from the cell cycle and reduced mitotic potential. Postnatal hypoxemia prolongs, whereas hyperoxemia narrows the postnatal proliferative window of CMs (Puente et al., 2014). A rare population of hypoxic CMs can promote cell proliferation via HIF-1α-regulated cell stress signaling (Guimarães-Camboa et al., 2015), and hypoxic CM populations contribute to new CM formation (Kimura et al., 2015). In addition, the regenerative response of cardiomyocytes in mice exposed to gradual systemic hypoxemia 1 week after the induction of myocardial infarction became robust, resulting in decreased myocardial fibrosis and improvement of left ventricular function (Nakada et al., 2017).

Neuregulin 1 (NRG1) belongs to the epidermal growth factor gene family. It is expressed in endothelial cells and exerts biological functions via the ErbB family of tyrosine kinase receptors. NRG1/Erb signaling promotes CM proliferation and is a promising candidate for restoring cardiac function after injury. Activating either NRG1 (Bersell et al., 2009; Cohen et al., 2014; Polizzotti et al., 2015) or ErbB2/4 (Bersell et al., 2009; Belmonte et al., 2015; D’Uva et al., 2015) improved CM proliferation, suggesting that the NRG1/Erb signaling pathway is conserved and thus might serve as an effective therapeutic strategy for heart diseases. Recombinant human NRG1 is currently being evaluated in clinical trials of agents to treat chronic heart failure.

Other signaling pathways, such as Wnt/β-catenin (Kerkela et al., 2008; Fan et al., 2018) and Jak/Stat (Fang et al., 2013; Miyawaki et al., 2017) also stimulate CM cell-cycle re-entry. A recent report using a cocktail of five small molecules which increase CM proliferation revealed lactate-LacRS2-mediated signaling as a novel mechanism for cardiomyocyte cell-cycle re-entry (Du et al., 2022). These multiple signaling pathways within CMs crosstalk and stimulate the proliferation of extant CMs (Lin et al., 2015). Therefore, manipulating several cell cycle-related signaling pathways will be a promising strategy with which to stimulate CM proliferation.

**The Effect of Endocardial and Epicardial Factors on Cardiac Regeneration**

As mentioned above, several important factors (for example, Notch, Agrin, and NRG1) to stimulate CM proliferation are expressed in non-CMs. Endocardium and epicardium are especially important in CM regeneration. The production of retinoic acid in the endocardium and epicardium is necessary for zebrafish heart regeneration and CM proliferation (Kikuchi et al., 2011). Fibronectin, which is secreted from the epicardium, can indirectly affect the process of cardiac regeneration near the injury site (Wang et al., 2013). Hand2, one of the important factors for direct reprogramming, is also expressed in the epicardium in
addition to the myocardium during cardiac injury and impacts cardiac regeneration (Schindler et al., 2014). In adult mammalian heart, epicardial (but not myocardial) follistatin-like1 (Fstl1) can promote cell cycle re-entry and division of pre-existing CMs, thereby improving cardiac function and survival in murine and swine models of myocardial infarction (Wei et al., 2015). In addition to CM proliferation, revascularization after cardiac injury is regulated by epicardial Cxcl12/Cxcr4 and endocardial Vegfa signaling (Marín-Juez et al., 2019). All of these reports indicate that endocardium and epicardium play a crucial role for cardiac regeneration in response to cardiac injury.

CONCLUSION

CMs usually lose their proliferative capacity in adult mammals. This largely limits heart regeneration after injury, which leads to adverse cardiac remodeling and heart failure. The mechanisms and the possibility of heart regeneration have been investigated for decades. In this review, we summarized the major approaches to manipulate cardiomyocyte plasticity for heart regeneration, namely iPSC-CM induction, direct reprogramming cardiac fibroblasts into CMs, and using molecules and signaling pathways to promote cell-cycle re-entry and the mitosis of extant CMs. All three strategies provide hope for heart regeneration and functional recovery in the clinical setting. However, their clinical applications have several limitations. For example, persistent and uncontrolled expression of miR-199a in pigs resulted in myocardial infiltration by proliferating CMs with a poorly differentiated myoblastic phenotype that leads to sudden arrhythmic death (Gabisonia et al., 2019). Similarly, although Notch and Wnt signaling is known to augment CM proliferation, their hyperactivation was shown to contrarily suppress heart regeneration (Zhao et al., 2014, 2019). Therefore, precise cardiac targeting for the delivery of therapeutics, as well as exquisite manipulation of temporally overexpressed target genes, would be of great importance. For the interventions to stimulate CM proliferation, a combination of genetic perturbation and single-cell analysis will be a powerful tool to identify novel therapeutic targets and also useful to identify optimal combinations of multiple target genes. Chemical compounds which regulate the key signaling pathways mentioned in this review will also be alternative choices.

Since the technology of high-throughput drug screening has made great strides in recent years by the contribution of computer science such as machine learning and deep learning, novel drugs that produce robust proliferation in CMs may be discovered in the near future. Multidisciplinary cooperation is also needed for a more comprehensive and systematic understanding of cardiomyocyte plasticity to improve the safety and efficiency of heart regeneration. The future promises an important breakthrough in this field when various concerns and technical restrictions regarding heart regeneration are overcome.

AUTHOR CONTRIBUTIONS

TK wrote the manuscript and designed figure. SN critically revised the manuscript and contributed to the figure design. All authors have contributed to the manuscript and approved the submitted version.

FUNDING

This work was supported by grants from a Grant-in-Aid for Young Scientists (to TK), the Japan Foundation for Applied Enzymology (to SN and TK), the SENSHPIN Medical Research Foundation (to SN and TK), the Kanai Foundation for the Promotion of Medical Science (to SN), MSD Life Science Foundation (to SN and TK), The Tokyo Biomedical Research Foundation (to SN), Astellas Foundation for Research on Metabolic Disorders (to SN), The Novartis Foundation (Japan) for the Promotion of Science (to SN), the Japanese Circulation Society (to SN), the Takeda Science Foundation (to SN), the Cell Science Research Foundation (to SN), a Grant-in-Aid for Scientific Research (A) (to SN), AMED (JP22ek0210152, JP21gm6210010, JP20bm0704026, JP22ek0210141, JP22ek0109440, JP22ek0109487, JP22gm0810013, JP22km0405209, JP21ek0210118, JP21ek0109406, JP22ek0109543, JP22ek0109569, JP21tm0724601, JP22ama121016, JP22ek0210172, JP22ek0210167) (to SN), and JST FOREST Program, Grant Number 21466223 (to SN).

ACKNOWLEDGMENTS

We thank editage for English proofreading.
Complex at Cardiac Super Enhancers to Promote Direct Reprogramming. *Nat. Cell Biol.* 23, 467–473. doi:10.1038/s41556-021-00668-z

Gemmill, C., Li, D., Duan, M., Yu, W.-M., Preininger, M. K., Jha, R., et al. (2019). Targeting HIF-1α in Combination with PPARα Activation and Postnatal Factors Promotes the Metabolic Maturation of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes. *J. Mol. Cell. Cardiol.* 132, 120–135. doi:10.1016/j.yjmcc.2019.05.003

Gomez-Garcia, M. J., Quesnel, E., Al-attar, R., Laskary, A. R., and Lalafm, M. A. (2021). Maturation of Human Pluripotent Stem Cell Derived Cardiomyocytes *In Vitro and In Vivo. Seminars Cell & Dev. Biol.* 118, 163–171. doi:10.1016/j.semcdb.2021.05.022

Grego-Bessa, J., Luna-Zurita, L., del Monte, G., Bolós, V., Melgar, P., Arandilla, A., et al. (2007). Notch Signaling Is Essential for Ventricular Chamber Development. *Dev. Cell* 12, 415–429. doi:10.1016/j.devcel.2006.12.011

Guimarães-Camboa, N., Stowe, J., Aneas, I., Sakabe, N., Cattaneo, P., Henderson, L., et al. (2015). HIF1α Represses Cell Stress Pathways to Allow Proliferation of Hypoxic Fetal Cardiomyocytes. *Dev. Cell* 33, 507–521. doi:10.1016/j.devcel.2015.04.021

Haginawa, S., Sadahiro, T., Kojima, H., Isomi, M., Tamura, F., Kurotsu, S., et al. (2019). Tbx6 Induces Cardiomyocyte Proliferation in Postnatal and Adult Mouse Hearts. *Biochem. Biophys. Res. Commun.* 513, 1041–1047. doi:10.1016/j.bbrc.2019.04.021

Hara, H., Takeda, N., Kondo, M., Kubota, M., Saito, T., Maruyama, J., et al. (2018). Discovery of a Small Molecule to Increase Cardiomyocytes and Protect the Heart After Ischemic Injury. *JACC Basic Transl. Sci.* 3, 639–653. doi:10.1016/j.jactls.2018.07.005

Hashimoto, H., Wang, Z., Garry, G. A., Malladi, V. S., Botten, G. A., Ye, W., et al. (2019). Cardiac Reprogramming Factors Synergistically Activate Genome-Wide Cardiogenic Stage-Specific Enhancers. *Cell Stem Cell* 25, 69–86.e5. doi:10.1016/j.stem.2019.03.022

Hatzistergos, K. E., Williams, A. R., Dykxhoorn, D., Bellio, M. A., Yu, W., and Hare, J. M. (2013). Tumorigenicity Assay Essential for Facilitating Safety Studies of hiPSC-Derived Cardiomyocytes for Clinical Application. *Sci. Rep.* 9, 1–10. doi:10.1038/s41598-018-38325-5

Jayawardena, T. M., Egennazarov, B., Finch, E. A., Zhang, L., Payne, J. A., Pandya, K., et al. (2012). MicroRNA-Mediated *In Vitro and In Vivo* Direct Reprogramming of Cardiac Fibroblasts to Cardiomyocytes. *Circ. Res.* 110, 1465–1473. doi:10.1161/CIRCRESAHA.112.269035

Jayawardena, T. M., Finch, E. A., Zhang, L., Hadgkinson, C. P., Pratt, R. E., et al. (2015). MicroRNA-Mediated Cardiomyocyte Reprogramming *In Vitro and In Vivo*. *Circ. Res.* 116, 418–424. doi:10.1161/CIRCRESAHA.116.304510

Jenné, D., Melenovsky, V., Stehlik, J., Staněk, V., Kettner, J., Kautzer, J., et al. (2021). Heart Failure After Myocardial Infarction: Incidence and Predictors. *Eur. Heart Fail.* 8, 222–237. doi:10.1002/euhf.13144

Kawaguchi, S., Soma, Y., Nakajima, K., Kanazawa, H., Tohyama, S., Tabei, R., et al. (2019). Intramyocardial Transplantation of Human iPSC-Derived Cardiac Spheroids Improves Cardiac Function in Heart Failure Animals. *JACC Basic Transl. Sci.* 6, 239–254. doi:10.1016/j.jactls.2020.11.017

Kawai, Y., Tohyama, S., Arai, K., Tamura, T., Soma, Y., Fukuda, K., et al. (2022). Scaffold-Free Tubular Engineered Heart Tissue from Human Induced Pluripotent Stem Cells Using Bio-3D Printing Technology *In Vivo*. *Front. Cardiocras. Med.* 8, 1–11. doi:10.3389/fcmd.2021.806215

Kawamura, M., Miyagawa, S., Fukushima, S., Aitou, M., Kimi, K., Funakoshi, S., et al. (2017). Enhanced Therapeutic Effects of Human iPSC-Derived Cardiomyocyte by Combined Cell-Sheets with Omental Flap Technique in Porcine Ischemic Cardiomyopathy Model. *Sci. Rep.* 7, 1–11. doi:10.1038/s41598-017-08869-z

Kerkela, R., Kockertiz, L., MacAulay, K., Zhou, J., Doble, B. W., Behm, C., et al. (2008). Deletion of GSK-3β in Mice Leads to Hypertrophic Cardiomyopathy Secondary to Cardiomyoblast Hyperpolarization. *J. Clin. Invest.* 118, 3609–3618. doi:10.1172/JCI36245

Kikuchi, K., Holdway, J. E., Major, R. J., Blum, N., Dahn, R. D., Begemann, G., et al. (2011). Retinoic Acid Production by Endocardium and Epicardium Is an Injury Response Essential for Zebrafish Heart Regeneration. *Dev. Cell* 20, 397–404. doi:10.1016/j.devcel.2011.01.010

Kimura, W., Xiao, F., Canseco, D. C., Muralidhar, S., Thet, S., Zhang, H. M., et al. (2015). Hypoxia Fates Mice Identifies Cycling Cardiomyocytes in the Adult Heart. *Nature* 523, 226–230. doi:10.1038/nature14582

Kuppusamy, K. T., Jones, D. C., Sperber, H., Madan, A., Fischer, K. A., and Bergmann, O. (2017). Cardiomyocyte Renewal in the Neonatal Heart. *Circ. Res.* 123, 1208–1221. doi:10.1161/CIRCRESAHA.116.313249

Lam, N. T., and Sadek, H. A. (2018). Neonatal Heart Regeneration. *Circulation* 34, 412–423. doi:10.1161/CIRCULATIONAHA.118.036488

Lázár, E., Sadek, H. A., and Bergmann, O. (2017). Cardiomyocyte Renewal in the Neonatal Heart: Insights from the Full-Out. *Eur. Heart J.* 38, 2333–2342. doi:10.1093/eurheartj/ehx343

Le Bras, A. (2018). Dynamics of Fibroblast Activation in the Infarcted Heart. *Nat. Rev. Cardiol.* 15, 379. doi:10.1038/s41569-018-0025-9

Leach, J. P., Heallen, T., Zhang, M., Rahmani, M., Morikawa, Y., Hill, M. C., et al. (2017). Hippo Pathway Deficiency Reverses Systolic Heart Failure After Infarction. *Nature* 550, 260–264. doi:10.1038/nature24045

Lin, X., Xu, C., Wilson, G., Zhu, K., Hazeltine, L. B., Azarin, S. M., et al. (2012). Hypoxia Fates Mice Identifies Cycling Cardiomyocytes in the Adult Heart. *Nature* 523, 226–230. doi:10.1038/nature14582

Lian, X., Hsiao, C., Wilson, G., Zhu, K., Hazeltine, L. B., Azarin, S. M., et al. (2012). Hypoxia Fates Mice Identifies Cycling Cardiomyocytes in the Adult Heart. *Nature* 523, 226–230. doi:10.1038/nature14582

Lin, Z., Von Gise, A., Zhou, P., Gu, F., Ma, Q., Jiang, J., et al. (2014). Cardiac-Specific YAP Activation Improves Cardiac Function and Survival in an
Zhao, L., Ben-Yair, R., Burns, C. E., and Burns, C. G. (2019). Endocardial Notch Signaling Promotes Cardiomyocyte Proliferation in the Regenerating Zebrafish Heart Through Wnt Pathway Antagonism. Cell Rep. 26, 546–554.e5. doi:10.1016/j.celrep.2018.12.048
Zhao, L., Borikova, A. L., Ben-Yair, R., Guner-Ataman, B., MacRae, C. A., Lee, R. T., etc. (2014). Notch Signaling Regulates Cardiomyocyte Proliferation During Zebrafish Heart Regeneration. Proc. Natl. Acad. Sci. U.S.A. 111, 1403–1408. doi:10.1073/pnas.1311705111
Zhao, Y., Londono, P., Cao, Y., Sharpe, E. J., Proenza, C., O’Rourke, R., etc. (2015). High-Efficiency Reprogramming of Fibroblasts into Cardiomyocytes Requires Suppression of Pro-Fibrotic Signalling. Nat. Commun. 6. doi:10.1038/ncomms9243
Zheng, Q., Bao, C., Guo, W., Li, S., Chen, J., Chen, B., etc. (2016). Circular RNA Profiling Reveals an Abundant circHIPK3 that Regulates Cell Growth by Sponging Multiple miRNAs. Nat. Commun. 7, 11215. doi:10.1038/ncomms11215
Zhou, H., Dickson, M. E., Kim, M. S., Bassel-Duby, R., and Olson, E. N. (2015). Akt1/Protein Kinase B Enhances Transcriptional Reprogramming of Fibroblasts to Functional Cardiomyocytes. Proc. Natl. Acad. Sci. U.S.A. 112, 11864–11869. doi:10.1073/pnas.1516237112
Zhou, H., Morales, M. G., Hashimoto, H., Dickson, M. E., Song, K., Ye, W., etc. (2017). ZNF281 Enhances Cardiac Reprogramming by Modulating Cardiac and Inflammatory Gene Expression. Genes. Dev. 31, 1770–1783. doi:10.1101/gad.305482.117
Zhou, Y., Liu, Z., Welch, J. D., Gao, X., Wang, L., Garbutt, T., etc. (2019). Single-Cell Transcriptomic Analyses of Cell Fate Transitions During Human Cardiac Reprogramming. Cell Stem Cell 25, 149–164.e9. doi:10.1016/j.stem.2019.05.020
Zhu, Y., Wang, L., Vaseghi, H. R., Liu, Z., Lu, R., Alimohamadi, S., etc. (2016). Bmi1 Is a Key Epigenetic Barrier to Direct Cardiac Reprogramming. Cell Stem Cell 18, 382–395. doi:10.1016/j.stem.2016.02.003
Zhu, D., Li, Z., Huang, K., Caranasos, T. G., Rossi, J. S., and Cheng, K. (2021a). Minimally Invasive Delivery of Therapeutic Agents by Hydrogel Injection into the Pericardial Cavity for Cardiac Repair. Nat. Commun. 12, 1–10. doi:10.1038/s41467-021-21682-7
Zhu, Y., Do, V. D., Richards, A. M., and Foo, R. (2021b). What We Know about Cardiomyocyte Dedifferentiation. J. Mol. Cell. Cardiol. 152, 80–91. doi:10.1016/j.yjmcc.2020.11.016

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Ko and Nomura. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.